54 - The Effect of Supplementing CLOSTAT 500 (Bacillus Subtilis PB6) to Yearling Steers in a Commercial Feedyard on Health, Salmonella Spp. Prevalence, Feedlot Performance and Carcass Characteristics

Thursday, June 30, 2022

8:50 AM – 9:05 AM CT

Location: Oklahoma City Convention Center, 301 C/D

Presenting Author(s)

Sara J. Trojan, PhD

Owner
Peak Beef Cattle Nutrition and Management Consulting LLC
CASPER, Wyoming

Author(s)

PB

Paul Rand R. Broadway

USDA-ARS Livestock Issues Research Unit
New Deal, TX
Nicole C. Burdick-Sanchez

USDA-ARS Livestock Issues Research Unit
New Deal, TX
JC

Jeff A. Carroll

Research Leader
USDA-ARS Livestock Issues Research Unit
New Deal, TX
KH

Kristin E. Hales

Thornton Distinguished Chair
Texas Tech University
Lubbock, TX
AW

Alyssa B. Word, PhD

Cactus Research
Amarillo, TX
KK

Kendall J. Karr, PhD

Cactus Research
Amarillo, TX
BH

Ben P. Holland, PhD

Director of Business Development and Operations Analysis
Cactus Feeders
Canyon, TX
GE

Guy Ellis

Cactus Feeders
Amarillo, TX
CM

Casey Maxwell, PhD

Cactus Feeders
Amarillo, TX
LC

Landon Canterbury

Kemin Industries
Des Moines, IA
TL

Tyler Leonhard

Kemin Industries
Des Moines, IA
DL

Doug LaFleur

Kemin Industries Inc.
Des Moines, IA
JH

Jerilyn Hergenreder

Kemin Industries Inc.
Des Moines, IA

Abstract: Crossbred beef steers, n = 2,100; 313 ± 38 kg initial body weight (BW) were used to evaluate Bacillus Subtilis PB6 supplementation to yearling steers. Cattle were blocked by arrival date and assigned randomly to pen within block; pens were randomly assigned to treatment within block. Treatments, replicated in 15 pens/treatment with 70 steers/pen, included: 1) control (CON), diets containing no supplemental direct fed microbials; 2) CLOSTAT (CLO), diets supplemented with 0.5 g/animal/d Bacillus subtilis PB6 (CLOSTAT 500, Kemin Industries, Des Moines, IA). Supplementing CLO decreased morbidity (P = 0.03), 10.38% (CLO) vs. 13.43% (CON), decreased the percentage of cattle treated once for bovine respiratory disease (BRD; P < 0.01), 9.14% (CST) vs. 12.76% (CON), and decreased BRD re-treatment rate (P = 0.03). Mortality did not differ among treatments (P = 0.23). Cattle removed from the study tended to be less for CLO than CON (53 vs. 73 animals, respectively, P = 0.06). The prevalence of fecal Salmonella was not different among treatments (P ≥ 0.35). Overall fecal Salmonella counts tended to be less for CLO (1.59 log CFU/g) than for CON (2.04 log CFU/g; P = 0.07). Concentration of Salmonella in subiliac lymph nodes did not differ by treatment (P = 0.62); however, mean prevalence of lymph node Salmonella decreased 46% by CLO (28.66% vs. 15.48%, CON vs. CLO, respectively,P = 0.46). With dead animals and removals included, final BW was heavier for CLO steers than CON, (P = 0.05), and average daily gain (ADG; P = 0.08), and gain efficiency (G:F, P = 0.06) tended to be greater for CLO than CON. With dead animals and removals excluded, final BW, ADG, and G:F did not differ among treatments (P ≥ 0.30). Carcass traits were not different between treatments (P ≥ 0.15). Supplementing CLO improved health outcomes of yearling steers.